want to set up a quarry what equipments do i need,The Quarry Story - Vulcan MaterialsWe take big rocks out of quarries and make smaller rocks and sand by crushing them. . Once we obtain the proper permits, equipment is purchased, roads are built to the facility . We install special water systems so we can recycle the water we use in . Once we have the land prepared we are ready to begin mining rock.want to set up a quarry what equipments do i need,Top Operations: Dolese Brothers' Davis Quarry - Aggregates ManagerSep 16, 2015 . We'd have to build another mill to handle the extra load, though. .. We do still have some of the old equipment, and it's not spare equipment, so they . We want to get it back to as natural a state as we can and keep it that way.National Quarry Services, Inc. | LinkedInSee who you know at National Quarry Services, Inc., leverage your . We have the equipment and experienced labor force necessary to fulfill any . Follow National Quarry Services, Inc. to stay up-to-date with news, articles . Candidate should possess knowledge of diesel engines, hydraulics and . Like Comment Share.
Jun 13, 2013 . Rock quarries hold great potential for financial growth. When owned . All you need to do is get the business up andrunning. If you have the.
Jun 20, 2017 . If it isn't managed well, surface water and groundwater can collect in the . to gather the elevation data needed to make water-management decisions. . The 1400 acre aggregate quarry supplies various line . Although Tecia first set out to gather elevation data and stockpile . You Know You Want It.
Amazon: Quarry's List (9781783298853): Max Allan Collins .
But what does Quarry have that the new man wants? .. Thomas, he knows how to build a maze but not lose his readers in it before showing them a way out.
Using monitoring equipment from Instantel, you can record and monitor vibration, . Industry guidelines have been developed to provide safe guidelines for . reports and you want the public to be able to view event reports, you can set . It records up to 65,536 samples per second to give you more resolution in your data.
We take big rocks out of quarries and make smaller rocks and sand by crushing them. . Once we obtain the proper permits, equipment is purchased, roads are built to the facility . We install special water systems so we can recycle the water we use in . Once we have the land prepared we are ready to begin mining rock.
Sep 4, 2018 . Alternative titles for this job. Miners and quarry workers operate machinery, vehicles and equipment to extract and process minerals and rocks.
Quarry Worker careers ; learn about becoming a Quarry Worker and what does it take . drilling - setting up and operating drilling equipment; maintenance workers . to follow instructions; have numeracy skills to work out material quantities. . If you would like to know anything about Quarry Worker that does not appear on.
Pleasant Garden residents don't want quarry, may not have a choice .
Aug 12, 2017 . Residents worry their lives will be disrupted by the noise and traffic . for an updated set of conditions and a special-use permit to allow for mining. . in Wake County, but so far only two residents have signed up. . But earlier this year the company did just that, hauling heavy equipment down the driveway to.
Line Quarry Increases Yearly Production Capacity up to 1.5 Million Tons . were designing the plant I didn't want to come back and say we should have done .. They use equipment from Stedman and other top manufacturers to create a.
have the expertise or equipment to do so and he or she hires .. place at the quarry setting out the operator's name, .. Like pedestrians, they should ideally be.
This handbook sets forth procedures for conducting inspections of Metal and Nonmetal .. may wish to discuss these requests with the appropriate Office of the Solicitor. . In that regard, they should always have the equipment and supplies . check-in and check-out purposes (for field offices with underground mines);.
Aug 4, 2017 . Photograph of a quarry site and earth moving equipment .. Authority must apply to Earth Resources in writing and obtain approval if they wish to . The Code sets out the minimum mandatory requirements that Work Authority .. The Rural Water Authority will need to be contacted if a small quarry requires:.
Dec 15, 2017 . This guide is not an exhaustive description of items, nor a tutorial on using each item. . To use the Builder as a quarry, you'll need to make a Shape Card . This will change the area to go up 100 blocks and down 100 blocks. . You may want to create a dedicated power system for the Builder so that your.
However, if you cannot afford to set up a quarry, you can settle for being a wholesaler. . Some of the equipment needed include crushers, excavators and excavator . If you can afford it, purchase a few heavy-duty haulage vehicles like tippers.
Jun 8, 2015 . The proposals would require many businesses to add all but the shortest leases to their balance sheets as liabilities, much like debt. Why lease? Equipment leasing is similar to a loan in which the lender buys and owns . The proposal would also set up a two-track system for how lease costs should be.
Mar 29, 2017 . Don't like this video? . Wales Construction Equipment Company Construction Equipment . News How to Set Up and Run a Quarry Plant for Granite,Dolomite How . a business In the set up of your business, it will often be necessary to . The NJ Business Action Center offers all of the information you need.
This Instructables Focus is on Build Craft and its very popular Quarry. . .mod-buildcraft/. You Will Need. 1x Quarry. 3x Stirling Engine . Place Down The Quarry Where You Want To Mine Out. .. Nintendo · Offbeat · Office Supplies · Paintball · Paper Airplanes · Party Tricks · PlayStation · Pranks and Humor.
Whether you need a pilot hole in a marble quarry, a core sampling hole, . We have the drill rig that will suit your needs. . Dimension stone equipment.
Before you can begin to seriously consider a quarry startup, you'll need to gain industry experience . If revenue-sharing sounds like an attractive avenue, be aware that your . It takes a lot of heavy equipment to operate a quarry effectively. . will need to be in place before you pull the first pound of material out of the ground.
Kerala: caught between quarries and sea erosion | Environment .
Oct 2, 2012 . IPS: Hills are vanishing as vast pits are gouged out to extract granite . and heavy equipment needed for massive quarrying were not available and . A group of disaster management experts proposed setting up of exclusive quarry zones, . up a paywall – we want to keep our reporting as open as we can.
This publication can help owners and operators of rock quarries in Missouri .. maintenance and repair of vehicles and machinery can create wastes as can . .dnr.mo/env/wpp/401/corps-map3.gif to find out which district covers your area. . If you want to use equipment at more than one site and both sites have.
And we'll wonder if we have it in us to face another five months of snow, ice, .. as well as toys, kids' clothing, and school supplies for an orphanage in Port au Prince. . But you'll want to act fast: the extension will continue for only a limited period . Quarry Hill resident Eva Smith never set out to be a "poster child" for active.
Aggregates Business Europe - More efficient quarrying with drone .
Through the Airware solution, quarry managers can safely obtain detailed and . the world's biggest-selling construction, quarrying and mining equipment manufacturer. . In Europe, potential customers want to set up some trials and need to.


text:
Hydroxychloroquine and Chloroquine Market to more than Double in 2020 – TechSci Research
Apr 28, 2020 | Corporate / SME News, News & Insights
Increase in prevalence of COVID-19 to drive demand for hydroxychloroquine and chloroquine across the globe
According to TechSci Research report, "Global Hydroxychloroquine and Chloroquine Market By Type, By Route of Administration, By Strength, By Application, By Region, Competition, Forecast & Opportunities, 2030", the global hydroxychloroquine and chloroquine market is projected to reach $ 285 million in 2020, predominantly on account of rising use of the drug in treating novel coronavirus COVID-19. Though, it has not been proven clinically that the drug can be used in treating coronavirus, but it has been identified that the drug is helpful in improving the early symptoms of the disease, especially the respiratory problems. Globally, Ipca and Cadila are among the top manufacturers of these drugs.
Browse 161 market data Figures spread through more than 110 Pages and an in-depth TOC on"Global Hydroxychloroquine and Chloroquine Market"
https://www.techsciresearch.com/report/chloroquine-and-hydroxychloroquine-market/4609.html
The global hydroxychloroquine and chloroquine market are segmented based on type, route of administration, strength, application and region. Based on type, the market can be categorized into injectables and tablets. The tablets segment is expected to dominate the market during the forecast period since these are cost effective. Based on route of administration, the market can be bifurcated into oral and intravenous. The oral segment is expected to dominate the market since the drug is generally consumed orally in the form of tablets. Based on application, the market can be categorized into rheumatoid arthritis, malaria, COVID-19 and others. The COVID-19 segment is expected to register the highest growth during forecast period since it has been identified that the drug can be used to treat the disease, though not clinically proven. Additionally, studies suggest that it is helpful in treating some symptoms of the disease and is being used widely in the treatment guidelines of COVID-19. Countries such as China, South Korea and Belgium have added hydroxychloroquine and chloroquine in their coronavirus disease treatment guidelines. Also, studies suggest that the drug has been helpful in treating few cases of the disease in France. Due to rising spread of the pandemic, FDA issued an Emergency Use Authorization for the treatment of novel coronavirus disease (COVID-19). Ipca Laboratories Ltd, Zydus Cadila, Novartis AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Rising Pharma Holdings Inc, Abcam plc, Mylan N.V, and Abbott are some of the leading players operating in global chloroquine market.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4609
Customers can also request for 10% free customization on this report.
"North America is expected to register significant growth in the hydroxychloroquine and chloroquine market during the forecast period, owing to the use of drug for treating COVID-19. Additionally, the drug is being used in the coronavirus treatment guidelines in various other countries. If it gets proven clinically that the drug can be used for the treatment of COVID-19, then this is expected to create lucrative opportunities for the market players in foreseeable future." said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
"Global Hydroxychloroquine and Chloroquine Market By Type, By Route of Administration, By Strength, By Application, By Region, Competition, Forecast & Opportunities, 2030" has evaluated the future growth potential of global hydroxychloroquine and chloroquine market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges and opportunities in global hydroxychloroquine and chloroquine market.
Browse Related Reports
United States Regenerative Medicine Market By Type (Cell-based immunotherapy & Cell therapy products, Gene therapy products, Tissue-engineered products, Others), By Material (Biologically Derived Material, Synthetic Material, Pharmaceuticals, Genetically Engineered Material, Others), By Application (Musculoskeletal Disorders, Wound Care, Oncology, Ocular Disorders, Diabetes, Others), By Region, Forecast & Opportunities, 2025
https://www.techsciresearch.com/report/united-states-regenerative-medicine-market/4517.html
Global Leukemia Therapeutics Market By Factor (Artificial ionizing radiation, Viruses, Others), By Severity (Acute, Chronic), By Blood Cell (Lymphocytic, Myelogenous), By Age Groups (0-15, 15-30, 30-50, 50+), By Sex (Male, Female), By Treatment (Targeted Therapy, Interferon Therapy, Radiation Therapy, Others), By Diagnosis (Blood test, Biopsy, Physical Exam, Imagining), By Route of Administration (Oral, Intravenous, Subcutaneous, Intramuscular, Intrathecal), By Drugs (Antimetabolites, Biosimilars, Others), By Region, Forecast & Opportunities, 2025
https://www.techsciresearch.com/report/leukemia-therapeutics-market/4534.html
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Email: sales@techsciresearch.com
Connect with us on Twitter – https://twitter.com/TechSciResearch
Connect with us on LinkedIn – https://www.linkedin.com/company/techsci-research
PreviousNUFAB launches Nonwoven fabric for front-line warriors
NextFamily business, is the culture of India and Spain Industry; Similarity makes comfort
The Pandemic Instigated an Export Boom in the Global Nonwoven Fabric Market
Smart Production Strategies, Sustainability And Stronger Customer Network- All Elements for Business Success @ India ITME Virtual Event For Textiles.
Eurofins concludes study into microfibre
IMMENSE OPPORTUNITY TO ACCELERATE TEXTILE RECYCLING IN EUROPE

redpajama_set_name: RedPajamaCommonCrawl


Fox And The Whale was Shortlisted for the 90th Oscars and nominated at the 2018 Canadian Screen Awards for Best Animated Short . More information on Film Festivals/ Awards here. You can also watch the film over on YOUTUBE and FACEBOOK .
Special Thanks to TIM NIELSEN who generously loaned the Field recordings / Sound library from which majority of the soundscape for the picture was designed.
Fox and the Whale is my first Short film. It is an entirely self financed independent production made with personal savings. My little experiment made over the course of 16 months. The production part of the film was just myself and my girlfriend Kim Leow. Kim was the sole CG character animator on the piece, and i did everything else. I hope you will enjoy scrolling through this page and getting a little glimpse behind the making of this short film.
I first started working on the film back in 2009. Development was often between freelance jobs. it was a process that stalled frequently. Apart from a handful of paintings it never went quite far. All that remains from those previous iterations is the title.
The design of the Fox as a biped was a turning point for me. I was always drawn to the potential for abstraction in the character designs. At it's simplest, the Fox design is a distillation of the story . The fox is designed as an arrow looking for it's path forward. A compass trying to find it's true north.
Originally i had conceived the film as all 2D. But being around my partner Kim, really warmed me to the idea of CG for the character animation. Slowly it took shape of a Hybrid project. Kim is an incredible animator. The limitation was always time and availability. The solution i chose was to design characters really rooted in simple silhouette, with the animation to be more based in physicality and pantomime than emotive/ dialogue driven performance. This kept production moving forward at a healthy pace. CG opened up a lot of potential for subtlety and nuance in mannerisms and the ability to iterate. All CG characters were built and rigged in Maya. The UV / texture was painted in Photoshop.
I took time off from all commercial work for 16 months to make Fox And The Whale. Storyboarding on the current iteration of the film started in January 2015. I spent about three and half months purely boarding and editing. Boards were done in Photoshop with the edit in Premiere. I tried not to spend too much time doing concept art at this stage. These 4 paintings below was all i did. The intent was to capture a sense of place and lighting. I wanted to spend any effort on concept art diverted to the colour scripting.
The Colour Script played a very important role in planning. I wanted to hit the major beats of the film, almost like keys in an animation sequence. This stage helped a lot once i was in the thick of production. I stayed as close as possible to the keys . There were a few shots that were replaced or edited out, but for the most part the film has maintained these initial colour beats. There was a specificity i was looking for. A lot of the inspiration came from a trip i took to Vancouver and Saltspring Island a few years back. The Pacific rainforest belt was always a big reference point for me. The hope was this stage would serve as the first ideas in creating a strong sense of place.
This was the first compositing test in aftereffects . The idea behind the test was to see how the hybrid approach could work. The fox is animated in CG in Maya. The little moths are animated in 2D in Photoshop.
The visual effects for the film, like fire, water, particles etc were achieved using AfterEffects. Most of these were done using plugins from Redgiant , called Trapcode. The choice with aftereffects was partly guided by my familiarity of the UI from being a longtime photoshop user. Also Creative cloud was a more affordable option for production. The learning curve was much smaller and all the packages from design through final render worked really great with each other.
Oddly enough one of the hardest sequences was this end scene among the bones. When i started working on the film, i was sure the most time consuming shots would be water, or some other effects scene, that would really hit a technical wall. When i look back at production, this was the sequence i spent the longest time on. Technically the least complex scene, but what made it hard was getting the idea of bones convincingly across. It took a while to really get the paintings and backgrounds right. The reference i would keep going back to was the colour keys .
On a brief visit to the Canadian Museum of Nature in Ottawa, I stumbled into the room where the BlueWhale skeleton was mounted. Kim spotted this , on our way out from another exhibit . It was a total happy accident. I spent the next few hours studying and taking enough reference. That really became my jumping-off point for the final solve of the background paintings.
Stills from the Bone Sequence in the final film.
A small note about software and hardware end of things. The film was entirely made from preproduction through post in my home studio, using commercially available software and hardware.
Color management and workflow on the software side was maintained through Adobe. On the hardware end, i was using HP Dreamcolor Z27x for colour accuracy through final render. Foley was recorded using a Zoom H5. Sound design was done using a pair of JBL LSR305's .
Fox and the Whale was a very independent production. As i mentioned above, It was entirely self financed from my personal savings. If you are interested in supporting this indie project, you can pick up the Art of Fox And the Whale Package via Gumroad.
The Art of book goes more in-depth into the production of this indie film. The Gumroad package comes with the Art of book PDF, Storyboards PDF, the full film in 2K resolution, Layered PSD background painting, Colour Script and screensavers. I hope you enjoy the book and the film!
COPYRIGHT © 2019, ROBIN JOSEPH. ALL RIGHTS RESERVED.


Have you ever wondered if your exterior door is not quite doing its job? It is something that is often overlooked people just forget that like everything else inside or on your home, a door will eventually need to be replaced. It is very crucial to check your door for signs that indicate wear from time to time. If you do need a new door, your current one may be allowing some unwanted things in. Below are some signs that tell you if you need to replace your exterior door. If you are ready for a door replacement in Lombard, an experienced company can help.
If your exterior door is quite drafty, this is a huge sign that a replacement is in order. A reason that older doors become drafty is because the seals that are around the door can crack or shrink. This door may be the culprit of why your home is so chilly in the winter or at night.
If your door happens to scrape along the floor when you close or open it, it may be time for a door replacement in Lombard. Old doors have the tendency to sag, causing them to drag across your floor and potentially damage it. To avoid floor issues, look into buying a new door.
Squeaky hinges are yet another sign you may need a door replacement. Maintenance can only do so much for this issue, and it is more cost effective just to get a new door. If your hinges have worn out, it could be possible that the actual door is wearing out, too. Additionally, worn hinges make it easier for the door to be forced open.
Have you been noticing a lot of ants in your home lately? If so, an old door that does not shut right can be letting them in. If you are ready to have a door replacement in Lombard, contact a reputable professional today.


text:
Q: Vertical-align in main css I have a wordpress site.
I have tried to add a table to my post.
Here is table code:

            area on the left

            Area on the right-1

            Area on the right-2

            Area on the right-3

After adding the table i see that main css contains a vertical-align:baseline for table, tbody, caption, tr, td,th. Because of that area on the right 1 is starting just on the right bottom corner of the area left.
When I remove the vertical-align from main css it effects all the site
How I can fix this?

A: You can override the property with vertical-align:top. Write like this:
table{
 vertical-align:top;
}

A: I found the solution like this

        area on the left

        Area on the right-1

        Area on the right-2

        Area on the right-3

redpajama_set_name: RedPajamaStackExchange


produced in accordance with the plans and these specifications.
specification shall conform to the requirements in this specification.
products will meet the ASTM specifications.
shall be produced in accordance with the approved drawings.
accordance with the ASTM standards indicated. Tests shall be performed for each 150 cu.
yd. of concrete placed, but not less frequently than once per week.
1. Products shall be stored, handled shipped and unloaded in a manner to minimize damage.
with methods or devices intended for this purpose.
products upon arrival at the jobsite.
CRSI Manual of Standard Practice.
imperfections, honeycombs, or other defects shall be permitted.
performed per industry standards or supplier specifications.
documents. The sample finishes shall be approved prior to the start of production.
areas, unless the surfaces are required by the design to be finished.
at which coarse aggregate particles break under chipping rather than being dislodged.
consolidating an appropriate repair material into the cavity.
are feasible and, if so, to establish the repair procedure.
Selecting Proportions for Normal, Heavyweight, and Mass Concrete (ACI 211.1).
for Structural Lightweight Concrete (ACI 211.2).
concrete is exposed to fresh water, or 0.45 or less if exposed to brackish water or sea water.
cement ratio of 0.40 or less.
limits given in Table 1.
other strengths are designated on the drawings.
shall be steel bars or welded wire fabric, or a combination thereof.
subjected can cause no product damage.
into rigid assemblies or by welding where permissible in accordance with AWS D1.4.
assure that the reinforcement does not move significantly during the casting operations.
shall be held rigidly in place so that they do not move significantly during casting operations.
segregation of the concrete is minimized and honeycombed areas are kept to a minimum.
in Cold Weather Concreting reported by ACI Committee 306.
is to come in contact shall be free from frost.
ials or materials containing ice shall not be used.
Concrete that freezes before its compressive strength reaches 500 psi shall be discarded.
Hot Weather Concreting reported by ACI Committee 305.
air temperature is below 50°F the curing period shall be extended.
not be caused which will impair the performance of the product.
Quality Control Manual for Precast Plants.
hauling, storage and proper handling of the precast concrete products.
led per the precast concrete producer's recommendation.
PROJECT AND PRODUCT REQUIREMENTS UPON REQUEST.


text:
The 2014 women's road cycling season was the third for the  Astana BePink Women's Team cycling team, which began as Be Pink in 2012.

Team Roster

Ages as of 1 January 2014 As of April 2014.

Riders who joined the team for the 2014 season

Riders who left the team during or after the 2013 season

Season victories

Footnotes

References

Astana BePink
Astana BePink Women's Team season
Astana BePink Womens Team

redpajama_set_name: RedPajamaWikipedia


85739 currently has 101 residential homes for sale on the market. The median list price is $299,900 or $156 / ft². These listings range from $229,000 in the lower quartile to $425,000 in the upper quartile. The average home currently for sale in 85739 is around 17 years old and 2,112 ft². There are currently 20 studio, 0 one-bedroom, 23 two-bedroom, 36 three-bedroom, and 22 four+ bedroom listings for sale.
Out of the 101 listings that are currently on the market, there are 0 condos, 77 houses, 3 townhouses, and 0 multifamilies. Our real-time inventory refreshes every hour, so that you see the best new inventory available on the market.
This search area is located within 85623. 85623 has 4,856 residents in 1,992 households. The median age of this zipcode is 51.4 with a majority of inhabitants married. At least 79.27% of those living in this zipcode currently own their homes. Roughly 0% of population here speak a language other than English at home.
The median income in this zipcode is $55,343, with an employment rate of 37.7%. It tends to take those living in 85623 an average of 34.3 minutes to get to work, with a majority commuting by car. Out of the total population of those 25 and older, 9.41% have a master's or above, 13.84% have a bachelor's, and 26.77% have a high school degree.
More broadly, 85623 is a part of Pinal County, Arizona. Pinal County, Arizona has around 397,604 residents, or 130,801 households with a median age of 38.3. Residents in this county have a median income of $51,190 and a home ownership rate of 72.51%.
Searching on Zillow 85739, Trulia, or Realtor.com? RealtyHop has the most comprehensive mortgage and property record data to help you make the best buying decision.


Evidence of associations between neighborhood built environments and transport-related physical activity (PA) is accumulating, but few studies have investigated associations with leisure-time PA.
EHP is a publication of the U.S. Federal Government, and its content lies in the public domain. No permission is required to reuse EHP content. However, use of materials published in EHP should be acknowledged (for example, "Reproduced from Environmental Health Perspectives") and a link provided to the article from which the material was reproduced.


Reservations are required. Please complete the tour reservations form. Please indicate any special needs your students may have. Reservations must be sent no less than 2 weeks in advance.
Tours are available Monday through Friday 9 a.m. to 5 p.m. Special exceptions may be made. Please inquire.
Tours are not available on State, Federal, and Longwood University holidays.
A tour confirmation will be mailed 1-2 weeks after receipt of reservation. If we are unable to accommodate your group you will be contacted immediately.
Groups are limited to 45 per hour. Groups will be spilt into smaller groups of 15-20 to insure an effective teaching environment is maintained during the visit. Faculty should plan on attending with their class.
Faculty members or their student assistant must accompany tours.
Please check your syllabus for test dates, holidays, special activities, etc. before scheduling your tour. If you must cancel a tour, please call 434-395-2648 immediately so that volunteer docents assigned to your group may be notified.
Tours are offered for free.
Enter only at the LCVA main entrance on the corner of Third and Main Streets in downtown Farmville. There is limited public parking adjacent to the LCVA. Please pay particular attention to signs designated as restricted parking. Metered parking is available on Main Street. Some free parking is available in the municipal parking behind the courthouse across the street from LCVA.
Prepare your students to look at and discuss works of art prior to your visit. Please discuss your students' educational needs with the LCVA museum educator prior to your visit to ensure that educational objectives are met during the visit. The LCVA enjoys designing tours to fit every course.


Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). We conducted a randomized, double-blind, Phase 2 trial in patients with uncomplicated S. aureus bacteremia.
Patients were randomized to either telavancin or standard therapy (vancomycin or anti-staphylococcal penicillin) for 14 days. Continuation criteria were set to avoid complicated S. aureus bacteremia. The primary end point was clinical cure at 84 days.
In total, 60 patients were randomized and 58 received ≥1 study medication dose (all-treated), 31 patients fulfilled inclusion/exclusion and continuation criteria (all-treated target [ATT]) (telavancin 15, standard therapy 16), and 17 patients were clinically evaluable (CE) (telavancin 8, standard therapy 9). Mean age (ATT) was 60 years. Intravenous catheters were the most common source of S. aureus bacteremia and ~50% of patients had MRSA. A similar proportion of CE patients were cured in the telavancin (88%) and standard therapy (89%) groups. All patients with MRSA bacteremia were cured and one patient with MSSA bacteremia failed study treatment in each group. Although adverse events (AEs) were more common in the telavancin ATT group (90% vs. 72%), AEs leading to drug discontinuation were similar (7%) in both treatment arms. Potentially clinically significant increases in serum creatinine (≥1.5 mg/dl and at least 50% greater than baseline) were more common in the telavancin group (20% vs. 7%).
This study suggests that telavancin may have utility for treatment of uncomplicated S. aureus bacteremia; additional studies are warranted. (Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia (ASSURE); NCT00062647).
Staphylococcus aureus bacteremia (SAB) is a devastating infection associated with high mortality, morbidity, and medical costs [1–3]. Approximately 40% of patients with SAB will have a complicated infection and more than 25% of these patients will die within the 12 weeks following their initial positive blood culture . Bacteremia is also a common form of invasive infection due to methicillin-resistant S. aureus (MRSA) .
Vancomycin, the most commonly used antibiotic in hospitalized patients with MRSA bacteremia, has several limitations , including the rise of strains with decreased susceptibility [6, 7] or resistance [8, 9] and suboptimal results for the treatment of patients with bacteremia due to methicillin-susceptible S. aureus (MSSA) [10, 11]. Despite the dramatic consequences of SAB and the limitations of vancomycin, only one registrational, open-label, randomized clinical trial in patients with SAB has been conducted , and vancomycin remains first-line therapy for MRSA bacteremia in most settings .
Telavancin is a lipoglycopeptide antibacterial agent exhibiting concentration-dependent bactericidal effects via a dual mechanism of action that combines inhibition of cell wall synthesis and disruption of membrane barrier function [14–16]. Telavancin has been approved in the U.S. and Canada for the treatment of patients with complicated skin and skin structure infections due to Gram-positive pathogens, and in Europe for the treatment of hospital-acquired pneumonia (including ventilator-associated pneumonia) due to MRSA, when alternative medicines are unsuitablea. Most recently (June 2013), telavancin was approved in the U.S. for hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of S. aureus when alternative treatments are not suitable. In vitro, telavancin is bactericidal against clinically important Gram-positive bacteria, including MSSA, MRSA, vancomycin intermediate susceptible (VISA) , and hetero-intermediate strains (hVISA) . Animal models of infection suggested that telavancin may be an effective treatment for SAB and endocarditis [17, 19, 20]. However, clinical experience in patients with SAB or endocarditis due to S. aureus treated with telavancin is limited [21, 22].
The ASSURE study (Telavancin for Treatment of Uncomplicated S. aureus Bacteremia) was conducted as a proof-of-concept study for telavancin compared with standard therapy for the treatment of uncomplicated SAB.
This proof-of-concept study was a Phase 2, randomized, double-blind, active-controlled, parallel group, multinational trial (NCT00062647), conducted from August 2003 through August 2006. Studies were approved by each institutional review board or ethics committee (see Additional file 1), and written informed consent was obtained from all patients or their legal representatives. Patients were randomized through an interactive voice response system in a 1:1 ratio, using a permuted block algorithm. The randomization was stratified by geographic region (within or outside the U.S.).
Patients were considered for the study if they were ≥18 years of age and had uncomplicated S. aureus bacteremia (with a qualifying blood culture [QBC]). Patients were excluded if they had any of the following: non-removable hardware (e.g., vascular stents or grafts placed within the last 6 weeks, joint prosthesis, or cardiovascular devices), removable source of infection (e.g., central catheter) that was not planned to be removed within 24 h from the QBC, significant cardiac valvular disease, any intra-cardiac mass or abscess defined by transthoracic or transesophageal echocardiography, prior history of endocarditis or osteomyelitis, recent infection with S. aureus requiring systemic antibacterial therapy within the last 30 days, evidence of metastatic complication (e.g., deep abscesses, endocarditis, osteomyelitis), or signs of vascular phenomena indicating potential arterial embolism (e.g., brain hemorrhage, pulmonary infarcts, Janeway lesions). Patients were also excluded if they had QTc (Fredericia's corrected) >470 msec, uncompensated heart failure or unstable angina within the last 30 days, abnormal serum levels of potassium or magnesium that could not be corrected, hypotension or oliguria unresponsive to resuscitation with fluid or vasopressors, recent systemic antimicrobial therapy potentially effective against S. aureus (>72 h within the last 7 days), neutrophil count <500 cells/mm3, HIV infection with CD4 count <100 cells/mm3 during the last 6 months, alanine aminotransferase or aspartate aminotransferase >5-fold the upper limit of normal or with Child-Pugh class B or C hepatic disease, immunosuppressant therapy, or concomitant use of agents containing cyclodextrin.
After initiation of study drug, patients were continued in the study only if they met all the following criteria: a) patients with MRSA bacteremia had been receiving vancomycin as initial therapy, b) removal of all removable foci within 24 h after the report of the QBC, c) negative follow-up blood cultures (FUBC) drawn 24 to 48 h after the report of the QBC, d) resolution of fever (≤38.0°C) within 72 h of the initiation of antistaphylococcal therapy, e) pre-treatment urine culture negative for S. aureus, f) transthoracic or transesophageal echocardiography, following QBC, showing no significant valvular disease, and g) no evidence of a metastatic complication on or before Day 5.
Patients were randomized to either telavancin 10 mg/kg intravenous (IV) q 24 h or standard therapy (vancomycin 1 g IV q 12 h, or nafcillin 2 g IV q 6 h, oxacillin 2 g IV q 6 h, or cloxacillin 2 g IV q 6 h). An anti-staphylococcal penicillin (ASP) could be selected if the baseline pathogen was known or highly suspected to be MSSA. The total duration of treatment with study medications was 14 days. Dummy infusions were used to maintain the study blinding and blinding of study medication was performed in the pharmacy.
Vancomycin was dosed per the U.S. Food and Drug Administration (FDA)-approved label. The dose of vancomycin could be adjusted by local institutionally accepted policies based on weight, serum levels, and/or renal function. Any dosage adjustments or obtention of serum levels of vancomycin were performed in a manner that maintained the study blind, usually by a designated pharmacist. Each site was to have submitted a blinding plan that was approved by the study sponsor.
The dose of telavancin was adjusted in patients with renal impairment: 7.5 mg/kg q 24 h and 10 mg/kg q 48 h for patients with creatinine clearance between 30 to 50 ml/min and <30 ml/min, respectively.
Vancomycin was continued in patients who were receiving vancomycin prior to randomization and were randomized to standard therapy. If the organism subsequently proved to be MSSA, vancomycin could have been changed to an ASP (nafcillin, oxacillin, or cloxacillin) at the investigator's discretion.
Clinical assessments were conducted at baseline and daily through to the end of therapy (EOT). EOT evaluation was performed within 72 h after administration of the last dose of study medication. A follow-up (FU) visit was scheduled 7 to14 days after EOT, and a test-of-cure (TOC) visit was scheduled 84 days after the start of study medication. At each evaluation, investigators assessed the signs, symptoms, and extent of the infection, surgical procedures, adverse events (AEs), and concomitant medications.
Two independent blood culture (BC) specimens were obtained within 24 to 48 h after the report of the QBC, EOT, and at the FU visit. Blood cultures were not obtained at TOC or at other time points, unless clinically indicated. All pathogens isolated were sent to a central microbiology laboratory for identification of genus and species and MIC testing.
Electrocardiograms were obtained in triplicate at baseline, every third day, and at EOT evaluation. Laboratory tests were performed at baseline, every 3 days during treatment, and at EOT and FU visits.
Clinical response assessed by the investigators at TOC was the primary end point of the study. Cure was defined by all the following criteria: resolution of clinical symptoms/signs associated with the bacteremia, no evidence of metastatic complications, all cultures negative for S. aureus after QBC cultures, and no non-study systemic anti-staphylococcal medication to which the baseline pathogen was susceptible. Failure was defined by any of the following: presence of symptoms/signs associated with the bacteremia, evidence of metastatic complications, positive blood culture for S. aureus, or death related to initial study infection after study Day 3. Indeterminate was defined by the inability to determine the outcomes mentioned above.
The following groups were defined for the analysis: a) all-treated (AT), patients who received ≥1 dose of study medication, b) all-treated target (ATT) patients who received study medication and fulfilled all inclusion/exclusion and continuation criteria (or who were approved for inclusion after careful review by the medical monitor to determine that the patient could be appropriately assessed), and c) clinically evaluable (CE), patients in the ATT population who received 12 to 16 days of study medication and whose study participation did not deviate from the protocol by more than pre-specified limits.
The objective of this study was to assess safety, tolerability, and explore efficacy (proof-of-concept). Sample size (60 patients randomized) was selected on the basis of clinical judgment in order to provide informative results consistent with the study objective. This study was not designed or powered to produce statistically significant results. The difference between rates of response within each treatment group was estimated with 95% confidence interval (CI), calculated using the method of Agresti and Caffo .
The protocol was amended to increase the daily dose of telavancin to 12.5 mg/kg and to include patients with complicated bacteremia, allowing 28 to 42 days of therapy in such patients. However, following U.S. FDA recommendations this amendment was rescinded shortly after its implementation.
A total of 60 patients were randomized in the study. Among those, 58 patients from 21 sites in five countries received at least one dose of study medication (AT population) (Table 1). Patients were enrolled in the U.S., Argentina, Spain, Singapore, and Hong Kong. Most patients were enrolled in the U.S. (73%). Figure 1 displays the disposition of patients into the study populations. Only one patient was included under the amendment allowing complicated bacteremia, received telavancin 10 mg/kg q 24 h for 24 days, and was discontinued due to an AE.
AE, adverse event; ECG, electrocardiogram; FU, follow-up visit; TOC, test-of-cure visit.
a Includes the only patient who was included under the amendment for complicated bacteremia and who was discontinued due to an AE after receiving 24 days of therapy.
b A patient may have failed more than one continuation criterion; in patients failing continuation criteria the reason for early drug discontinuation decided by the investigators may have been different from not meeting such continuation criteria.
c This patient also failed continuation criteria.
d One patient in this group also failed continuation criteria.
Patient disposition into the study populations. More than one reason may be present for patients to be excluded from all-treated target and/or clinically evaluable populations. SAB, S. aureus bacteremia; TOC, test of cure.
A total of 55% of patients in the telavancin group and 41% in the standard therapy group discontinued the study drugs early. The most common reason for early discontinuation of study drug due to continuation criteria failure was the presence of positive FUBC. Among telavancin-treated patients who discontinued the drug early because of a positive FUBC result, four of five had their FUBC obtained before starting telavancin. Study visits and reasons for early study drug discontinuation are displayed in Table 1.
Overall, demographics and clinical characteristics were similar in the two groups (Table 2; ATT population). Most patients were male, white, and the mean age was 60 years. Diabetes was common in both treatment groups. There were more obese patients in the telavancin treatment group. The source of bacteremia was identified in the vast majority of cases, with IV catheters being the most common source in both groups. All IV catheters identified as a source of infection were removed within 24 h after the report of the qualifying blood culture. The majority of patients in the telavancin and standard therapy groups received prior systemic antimicrobial therapy with vancomycin within 7 days prior to initiation of study medication. MRSA was isolated from the blood cultures of 47% and 50% of the telavancin and standard therapy patient groups, respectively.
IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus.
a Within 7 days prior to initiation of study medication.
All baseline isolates of S. aureus available for testing were susceptible to vancomycin at a minimum inhibitory concentration (MIC) of ≤1 μg/ml (n = 40; MIC90 = 1 μg/ml for both MRSA and MSSA) and to telavancin at an MIC of ≤0.5 μg/ml (n = 32; MIC90 = 0.5 μg/ml for both MRSA and MSSA). Telavancin MICs for these isolates were tested according to the Clinical Laboratory Standards Institute (CLSI) guidelines in place at the time that this study was performed and susceptibility was interpreted with the corresponding FDA breakpoints approved in 2009. The MIC testing methodology and corresponding FDA-approved breakpoints for telavancin have recently been revised and are published in the CLSI M100-S24 guidelines and telavancin product insert (March 2014), respectively.
In the standard therapy group, seven of 16 patients were treated with an ASP from the beginning and one patient was switched from vancomycin to ASP on study day 4 due to a blood culture being positive for MSSA on day 3.
The CE population was limited to eight patients in the telavancin and nine patients in the standard therapy group. A similar proportion of patients were cured in the telavancin (88%) and standard therapy (89%) treatment groups (Table 3). All patients with MRSA bacteremia were cured, and one patient with methicillin-resistant S. aureus bacteremia failed study treatment in each treatment group (Table 4). The patient who failed therapy in the telavancin group was a 73-year-old female with a peripheral catheter-related MSSA bacteremia whose blood cultures were positive on study Day 28 and was subsequently found to have osteomyelitis. The patient who failed therapy in the standard therapy group was a 75-year-old male with MSSA bacteremia from an unidentified source who died after being readmitted on study Day 48 with an intestinal ischemia and positive blood cultures for MSSA.
CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus.
ASP, anti-staphylococcal penicillin; IV, intravenous; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; N/A, not available; SAB, Staphylococcus aureus bacteremia.
Among CE patients, microbiological eradication at TOC was achieved in 88% of patients in the telavancin group and 78% of patients in the standard therapy group. The two patients who relapsed (one in each treatment group) were considered clinical failures and have already been described. In addition, one patient in the standard therapy group who was considered clinically cured at TOC had one of two BCs positive for MRSA. The most relevant characteristics and outcomes of patients in the CE population are described in Table 4.
AEs and serious AEs (SAEs) were more common in the telavancin group (Table 5), although only two patients in each group discontinued the study medication because of an AE. Overall types of AEs were similar in the two study groups. Most common AEs included pyrexia, headache, anemia, and rash. No individual SAE occurred in more than one patient per treatment group. Five and three patients died in the telavancin and standard therapy groups (17% vs. 10%), respectively. Among patients who died in the telavancin group, one patient withdrew consent after the first dose and died from endocarditis, two patients were discontinued early because of failure to meet continuation criteria (one with endocarditis and one with metastatic soft tissue abscess), and two patients died after completing study medication (one with prostate cancer and cardiorespiratory failure and one who the investigator deemed to have [probable] sepsis from the urinary tract). Among patients who died in the standard therapy group, one patient died with MSSA bacteremia and intestinal ischemia (described above), one patient developed endocarditis, and one patient died from a neuroleptic malignant syndrome. Potential clinically significant increases in serum creatinine (serum creatinine ≥1.5 mg/dl and at least 50% greater than baseline at any time point through the EOT visit) were more common in telavancin-treated patients (5/25 vs. 2/28). The rates of resolution (completely or partially resolved) were two of five telavancin patients and two of two vancomycin patients by the last study visit. Otherwise, laboratory abnormalities were similar between the study groups (Table 6).
ALT, alanine aminotransferase; AST, aspartate aminotransferase, ULN, upper limit of normal; WBC, white blood count.
a Includes laboratory assessments after initiation of study drug up to and including the earlier of the follow-up visit or 28 days after the last dose of study medication.
b Serum creatinine ≥1.5 mg/dl and at least 50% greater than baseline; includes patients with normal and abnormal values at baseline.
The ASSURE study is the first clinical trial evaluating telavancin in the treatment of patients with uncomplicated SAB. The study has provided several findings that should be noted.
This study provides proof-of-concept for telavancin in patients with uncomplicated SAB. Although cure rates in ATT patients were numerically higher (not statistically significant) in the standard therapy group, a similar proportion of CE patients were cured in the telavancin and standard therapy arm (88% vs. 89%) (Table 3). One patient in the standard therapy group who was considered cured had positive blood cultures during the FU visit. Although this patient should have been considered a clinical failure, the authors have chosen to be conservative in this report and maintain the original assessment. The only CE patient who failed in the telavancin group was found to have osteomyelitis several weeks after finishing therapy. While overall mortality of SAB in the pre-antibiotic era was over 80% , death rates still remain high (~30%) in contemporary series, particularly in patients with complicated disease [2, 25, 26]. The relatively low mortality found in this trial is consistent with both adequate antimicrobial therapy and selection of patients with uncomplicated disease.
Telavancin was tolerated in patients with uncomplicated SAB. Although AEs were more common in patients receiving telavancin, AEs leading to drug discontinuation were similar in the two groups. Consistent with a previously reported study, increases in serum creatinine were more common among telavancin-treated patients . Changes in serum creatinine appeared reversible when an adequate FU was obtained and other contributing factors removed. Apparent differences in mortality observed in the AT population should be analyzed with caution. The apparent higher mortality observed in the telavancin group may be related to the small study size, and the fact that three died after being withdrawn early due to complicated disease and two died of other underlying conditions–urinary tract infection/sepsis and prostate cancer.
Clinical identifiers of complications in patients with SAB have been well described and include delayed clinical and microbiological response to antibacterial therapy . Despite these observations, identifying patients with uncomplicated SAB at the initial evaluation is quite challenging. For example, in a study that identified clinical predictors of the presence of complicated S. aureus bacteremia among 724 prospectively identified patients, the risk for complications in patients with no identified risk factors was still ~16%. Moreover, the most powerful predictor of complicated S. aureus bacteremia, the presence of positive blood cultures at 48 to 96 h following the initial BC, was by definition unavailable at the time the patient was being considered for initial enrollment into the study . Our inability to accurately define the extent of the disease at baseline in the present study of uncomplicated SAB resulted in a significant limitation in both enrollment and clinical evaluability. This also highlights the significant unmet medical and antimicrobial development need for rapid diagnostic platforms that can reduce the time to identification of the etiology and extent of bacterial bloodstream infection.
This study has several important limitations. First, the small study size limited the interpretation of outcome data. Although a larger study would provide more definitive evidence, the ASSURE trial provides proof-of-concept that telavancin could potentially be an effective therapy to treat patients with uncomplicated SAB and warrants further study. Second, the diagnostic techniques using blood cultures to determine bloodstream infection are still far from ideal. Hopefully, in the future, molecular techniques (e.g., polymerase chain reaction [PCR]) for rapid determination of SAB and antibiotic susceptibilities will be used in both clinical care and in trials of new antimicrobial agents . Third, vancomycin was administered following local policies, and as such, adjustment according to trough levels was not mandatory. Although this fact may have resulted in inadequate dosing (high or low), only one patient with MRSA in the CE population experienced a late relapse, suggesting that vancomycin dosing was appropriate in most cases. There are also more recent recommendations on vancomycin dosing that were published after the start of this trial that will need to be considered in future studies. Lastly, the exclusion of patients with complicated disease resulted in a very small population of evaluable patients. There was also a possibility of underestimation of AEs due to the small sample size. In the absence of data from well-designed, adequately powered studies, physicians will continue to treat patients suffering from this life-threatening infection based on limited evidence on antibiotic efficacy.
This study represents the first proof-of-concept for telavancin in patients with uncomplicated SAB. Based on these results, additional studies of telavancin in patients with SAB, including complicated SAB, are warranted.
aTelavancin is a lipoglycopeptide antibiotic approved in the United States and Canada for the treatment of patients with complicated skin and skin structure infections due to susceptible Gram-positive pathogens, and in the United States and Europe for the treatment of hospital-acquired bacterial pneumonia, including ventilator-associated bacterial pneumonia (HABP/VABP) due to susceptible isolates of Staphylococcus aureus (methicillin-resistant strains [MRSA] only in Europe), when alternative medicines are unsuitable.
Michael M Kitt, an employee of Theravance at the time of the study, has since left the company.
Vancomycin intermediate susceptible Staphylococcus aureus.
The authors would like to thank the ASSURE study investigators. The ASSURE study was supported by Theravance, Inc. Editorial support during manuscript development was provided by Emily Howard, a medical writer formerly with Envision Scientific Solutions, funded by Theravance, Inc.
Martin E. Stryjewski has served as a consultant for Cempra, Cerexa, Furiex, Nabriva, PRA, The Medicines Company, Theravance, and Trius; has received grants from Duke University (NIH); and has received other financial support (including reimbursement for travel expenses and/or manuscript preparation) from Cempra, JMI Laboratories, and Theravance. Arnold Lentnek is an employee of Danbury Clinical Research and Infectious Disease Medical Practice of New York; has served as a consultant for Warburg Pincus Capital Investment; has received grants from Optimer; and has provided expert testimony for Sullivan Papain Block McGrath & Cannavo. William O'Riordan has received financial support related to being an ASSURE study investigator (including reimbursement for travel expenses) from Theravance. John Pullman has received grants and travel expenses reimbursement from Theravance; and has received payment for lectures/speakers bureaus from Astellas. Paul Anantharajah Tambyah has received grants from Sanofi-Pasteur and Theravance; has served as a consultant for AstraZeneca, GlaxoSmithKline, and Johnson & Johnson; has received payment for lectures/speakers bureaus from MSD and Novartis; has received payment for the development of educational presentations from Teleflex; and has received other financial support (including reimbursement for travel expenses) from 3M, Adamas, Fabentech, and Inviragen. Jose M. Miró has received financial support related to being an ASSURE study investigator from Theravance; has received grants from Cubist, Fondo de Investigaciones Sanitarias (Spanish Ministry of Health), National Institutes of Health, Novartis, and RIS-ISCIII (Spanish Network for AIDS Research, Instituto de Salud Carlos III); has participated on advisory boards for Cubist and Novartis; has served as a consultant for Abbott, Bristol-Myers Squibb, Cubist, Gilead Sciences, Merck, Novartis, Pfizer, Roche, and Theravance; has received payment for lectures/speakers bureaus from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Cubist, GlaxoSmithKline, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Schering-Plough, Theravance, and ViiV. Vance G. Fowler, Jr. has participated on advisory boards for Merck; has received grants from Advanced Liquid Logistics, Cerexa, Merck, MedImmune, National Institutes of Health, Novartis, Pfizer, and Theravance; has served as a consultant for Achaogen, Affinium, Astellas, Biosynexus, Cerexa, Durata, The Medicines Company, MedImmune, Novartis, Novadigm, Pfizer, and Theravance; is a patent holder by the National Center for Genomic Research; has received royalties from UpToDate; and has received payment for development of educational presentations from Cerexa, Cubist, and Theravance. Steven L. Barriere is an employee of, and holds equity securities of, Theravance. Michael M. Kitt was an employee of Theravance at the time of study conduct, and holds equity securities of Theravance. G. Ralph Corey has participated in advisory boards for Cempra, Cerexa, Inimex, Pfizer, and Trius; has served as a consultant for Cempra, Cerexa, Dr Reddy's Lab, Inimex, PolyMedix, Pfizer, PRA, Theravance, and Trius; has received grants from Innocoll, The Medicines Company, and Theravance; and has received other financial support (including reimbursement for travel expenses and manuscript preparation) from Theravance.
MES, AL, WO, JP, PAT, and JMM were study investigators. SLB and MMK were the sponsor medical monitors and were involved in the study concept/design and data analysis/interpretation. VGF was co-investigator and was involved in the study concept/design and data analysis/interpretation. GRC was the principle study investigator and was involved in the study concept/design and data analysis/interpretation. All authors were involved in preparation of the manuscript (via critical review) and approved the final version.


text:
Strategies & Tactics — Current Issue | Strategies & Tactics — June 2019 Issue
Faster Company: Strategies to Guide Technology, Influence the Future
By Grant McLaughlin
[simon carter]
Chatbots. Voice search. Augmented analytics. Our professional world is filled with ever-changing tools and tactics, just as our personal lives have been transformed by smartphones, social networks and streaming media.
Technology may change how we communicate, but this dynamic works the other way around, too: As professional communicators, our strategies can determine how we use technology.
Shape the media
For its April 2018 study "The Future of Well-Being in a Tech-Saturated World," Pew Research Center gathered varied opinions from experts. Some warned about the dangers of information overload and distractions from clickbait headlines. Others said digital technology can improve the future.
"Human beings want and need connection, and the internet is the ultimate connection machine," said Daniel Weitzner, principal research scientist and founding director of MIT's Internet Policy Research Initiative.
Most thought-provoking were responses from experts who urged a proactive stance to technological changes. "[People] need to learn how to use social media, and … not to be used by it," said Alexander Halavais, an associate professor in the School of Social and Behavioral Sciences at Arizona State University. People should "be able to shape the media they are immersed in," he said.
As communications professionals in a fast-moving culture, we must similarly help clarify the thinking, decisions and strategies that will affect humanity in the years ahead. Whether you work in media relations or internal communications, you can help shape opinions, motivate people and influence the future of our profession and our world.
Create strategic goals
As the marketing platform Intercom points out about technology purchases, "The 'shiny penny' approach (focus all your attention on the hottest tools in the market) or 'head in the sand' approach (fall victim to analysis paralysis and avoid choosing any tools) are no longer viable." It takes clear thinking to get results, and strategy must lead the charge.
As a communicator, you can bring the conversation back to your organization's goals by asking questions such as, "What is our message? Who do we want to engage? What do we want the audience to do? How will we keep the relationship going? How will we measure engagement?"
According to a 2018 Gartner Research report, marketing-technology expenses account for 29 percent of total marketing budgets. When spending those funds, it's easy to focus on features and prices instead of thinking about how new technology will work with existing tools and tactics and help the organization reach its goals. By emphasizing strategy upfront, you can help decision-makers avoid wasting money or adding unnecessary complexities.
As PR professionals, we must orchestrate the conversations that result from the powerful combination of technology and communication. Here are five tips for doing so:
Know what you want to accomplish. Many communications initiatives lack a clear objective that supports organizational goals. Others are fuzzy about the action the audience should take after hearing the message. Do you want people to download information, share a post or make a purchase? Are there multiple audiences to segment, representing different stages of the buyer's journey?
Know your audience's preferred communications channels. Segment your audience and analyze their favorite ways to interact with your business — backed up by research, if possible. Maybe they're millennial consumers who like to shop on Pinterest, business-to-business contacts who respond to email, or employees who post content on social media.
Create the flow. Now that you've established your goal and audience, choose the channels and map metrics to desired actions. Here's where the interplay begins. Connect strategy to technology so you can gather the data: Strategy takes the lead. Once the campaign begins, analyze the metrics and let them inform what you do next: Technology takes the lead. Repeat the cycle to continually enhance results.
Communicate clearly. Before launching your communications campaign, make sure everyone involved understands its goals, their own roles and what needs to be done. Marketing efforts are often marred by website landing pages that don't convey the message, tracking mechanisms that aren't set up correctly, or tools that don't function as expected.
Keep the conversation going. When the campaign is over, apply lessons you learned from it to your subsequent communications efforts. Test hypotheses to boost audience responses, and add new technology where it makes strategic sense.
Use technology to make a difference. The future is yours.
Grant McLaughlin, vice president, corporate affairs for Booz Allen Hamilton, brings a strategic edge to employee engagement and integrated marketing, reinventing the editorial voice and driving revenue with metrics aligned to client insights and data-driven targeting. His transformative team includes emerging technologists, digital marketers and analytical powerhouses. Follow him on Twitter @grantrmc.
Strategies & Tactics — June 2019 Issue


text:
Items All Souls Men's Club
All Souls Men's Club
Rare Book Division
Buttolph, Frank, 1850-1924
Image ID 4029675
Larger (2560px)
High Res (TIF format)
Free to use without restriction
The Buttolph collection of menus
Buttolph, Frank, 1850-1924 (Collector)
Shelf locator: 1920-0009
Extent: 18x14cm folded; 18x28cm open
Universal Unique Identifier (UUID): b637d540-c54a-012f-fc1c-58d385a7bc34
The New York Public Library believes that this item is in the public domain under the laws of the United States, but did not make a determination as to its copyright status under the copyright laws of other countries. This item may not be in the public domain under the laws of other countries. Though not required, if you want to credit us as the source, please use the following statement, "From The New York Public Library," and provide a link back to the item on our Digital Collections site. Doing so helps us track how our collection is used and helps justify freely releasing even more content in the future.
1850: Creator Born
1924: Creator Died
Rare Book Division, The New York Public Library. "All Souls Men's Club" The New York Public Library Digital Collections. 1920. https://digitalcollections.nypl.org/items/bf8b24be-ca12-4876-e040-e00a1806540b
Rare Book Division, The New York Public Library. "All Souls Men's Club" New York Public Library Digital Collections. Accessed February 2, 2023. https://digitalcollections.nypl.org/items/bf8b24be-ca12-4876-e040-e00a1806540b
Rare Book Division, The New York Public Library. (1920). All Souls Men's Club Retrieved from https://digitalcollections.nypl.org/items/bf8b24be-ca12-4876-e040-e00a1806540b
<ref name=NYPL>{{cite web | url=https://digitalcollections.nypl.org/items/bf8b24be-ca12-4876-e040-e00a1806540b | title= (text) All Souls Men's Club, (1920)|author=Digital Collections, The New York Public Library |accessdate=February 2, 2023 |publisher=The New York Public Library, Astor, Lenox, and Tilden Foundations}}</ref>


The 69th East Middleborough 4-H Fair takes place Saturday from 8:30 a.m. – 6:30 p.m. and Sunday from 8:30 a.m. – 5:30 p.m. Free admission and parking with animals and family fun for all. There will be exhibits and food options, too, at 183 Thomson Street (Rt. 105) in Middleborough.
Scituate touch a truck at Scituate Town Hall from 9 – noon today!
Friday morning summer story time wraps up today at the Paragon Carousel promptly at 10:30 a.m. and the carousel opens at 10:00 a.m. today. Rapunzel and Flynn Ryder will be the storytellers today! The event is free and guests may purchase ride tickets to join Rapunzel and Flynn Ryder on the carousel after the story.
Head to Tidmarsh Wildlife Sanctuary in Plymouth from 10:00 a.m. – 11:30 a.m. and join Education Coordinator Morgyn Ellis for a family ponding experience. Join Morgyn on an aquatic adventure as you explore the pond and the banks at Tidmarsh in search for some of the amazing creatures who call it home. You'll use nets and hand lenses to see tadpoles, frogs, fish and other critters up close! The cost is $5 for kid members and $7 for kid non-members – adults free. Register online or by calling 508.927.1200.
The 69th East Middleborough 4-H Fair takes place today from 8:30 a.m. – 5:30 p.m. Free admission and parking with animals and family fun for all. There will be exhibits and food options, too, at 183 Thomson Street (Rt. 105) in Middleborough.
It's open farm day today at Dalby Farm in Scituate from 10:00am to 12:00pm ($5/person, *street parking) you can drop by the farm (no registration necessary) and visit with the animals! The goats, sheep, chickens, ducks, geese, bunnies, pig and peacocks can't wait to see you! For just $5 a person, you can casually browse the farm and get to know the animals. A Farm-based educator will be available to answer any questions you might have. Pack a snack and soak in the farm scene at one of our picnic tables! Take the opportunity to do a little shopping in our Country Store, or learn about our birthday parties, Ladies Fitness Club, and other offerings! Head to 59 Grove Street in Scituate!
The 42nd annual Corn Festival at the South Shore Natural Science Center in Norwell takes place Saturday and Sunday September 15 and 16 from 10:00 a.m. – 4:00 p.m. The Corn Festival celebrates the fall harvest as well as the natural and cultural heritage of New England. The event includes all day activities like hay rides and craft demos as well as scheduled events like live animal presentations. Keep an eye on their website and Facebook page for the latest details.


Digital DJ has opened an art for millions, but as with any new hobby, the first step can feel scary - especially when you have to learn to use the software and hardware together to try their hand at DJ skills for the First time. It is where this series is the new "Your first day with ..." aims to help: It is addressed directly to the digital DJ for the first time that you put your hands on this particular software.
In this first article, we focus on one of the most used DJ applications in the world: Virtual DJ 8. We all you need to know to install it on your computer show, how to get on the right track and How to use it without a driver so you can quickly get to rocker! No detour, just a guideline to start now.
Before you start downloading and configuring Virtual DJ 8, we will quickly discuss the differences between the different versions: a free version of "Home User" and "Advanced User Home" and "Professional User" is paid.
License "Advanced User Home" gives full use of a DJ controller without time restriction. The price of the license varies from the US $ 49 to the US $ 199, depending on which controller you have. I recommend checking this page on your site to determine how much it costs for the controller. Note that if you intend to get cash DJ with Virtual DJ 8 does not aim to do with this license as it is considered to use "professional" of it.
"User Home" version can be downloaded from the website and used for free for the time you want. It is so you can try Virtual DJ 8, "provided they do not use for professional purposes" (i.e., not making money using it as a DJ, but somehow Recording or outside.) There is also a 10-minute trial period that you can connect and use the DJ controller you each time the Virtual DJ 8 spear, which is an excellent way to Check how the device works with the software before committing to buy.
DJs mobile, club DJ or people who win by doing with Virtual DJ license 8 "professional user" is what is needed. It provides access and full use of all current and future driver DJs and also the only option that allows you to create your custom applications for dj controllers that do not work with Virtual DJ 8 directly in the box.
There are two types of licenses for business users: Infinity Pro, which is a one-time payment of US $ 299, or Subscriber Pro, which is a monthly payment of US $ 19. It gives you all the license benefits for professional use With access to all controllers.
I think $ 19 is a great value if you plan to take the controller and Virtual DJ 8 concerts in bars etc., and are allowed I suggest you if you want DJ with a driver, especially if you are In doubt for the driver plans to buy shortly.


text:
News and Information about vw phaeton
List of News and Information about vw phaeton on 4WheelsNews.com
Read the latest news and information about vw phaeton published on 4WheelsNews.com! View comments and pictures about vw phaeton on 4WheelsNews.com!
You also might be interested: vw phaeton, next-generation, diesel, plug-in hybrid, sedan, united states, hyundai, hyundai equus, luxury car, china, facelift, beijing auto show, bmw 7-series, mercedes-benz s-class
Next-generation VW Phaeton will get turbocharged direct injection diesel, plug-in hybrid engines
Turbocharged direct injection diesel and plug-in hybrid engines will be part of the powertrain offerings for the second generation of the Volkswagen Phaeton big luxury sedan when it is rolled out in the United States for the 2018 or 2019 model year, sources told Automotive News. The return of the Phaeton to the US has already been confirmed by Michael Horn, chief executive of Volkswagen Group of America.
The sources disclosed that the Phaeton will be available in a number of high-powered engines like a 450hp V-8 TDI and a 400hp-plus V-6 gasoline plug-in hybrid. The source, however, said that a top-of-the-line W-12 engine would not be offered in the Phaeton in the US.
While sources say the new Phaeton "is virtually developed and finished," VW is not hasty in replacing the first-generation Phaeton. The current Phaeton did not do well in the US and was scrapped in 2006, although it still sells in China.
Read the entire article Next-generation VW Phaeton will get turbocharged direct injection diesel, plug-in hybrid engines
Next-generation VW Phaeton will be more affordable as it will take on Chrysler 300, Ford Taurus SHO
We already know that the first-generation Volkswagen Phaeton was not quite a bestseller but it appears that the German carmaker will adopt a new strategy. According to Edmunds, the new Phaeton will become more affordable as it will take on cars such as the Chrysler 300 or the Ford Taurus SHO.
The first generation Phaeton has a sticker price of over $100,000, while the Ford Taurus SHO costs $40,805.
Meanwhile, a fully loaded 2014 Chrysler 300C John Varvatos Limited Edition with all-wheel drive costs $48,175. The Volkswagen Phaeton was a hand-built rival for cars made by BMW, Mercedes-Benz and Audi.
Read the entire article Next-generation VW Phaeton will be more affordable as it will take on Chrysler 300, Ford Taurus SHO
Volkswagen Phaeton to return to the United States
Volkswagen AG is planning to reintroduce the Phaeton to the United States, seven years after pulling out the luxury sedan from the country. VW had to pull out the Phaeton, its most expensive model, from the US due to weak. However, VW has been unable to crack the upscale segment in the US, and the Phaeton seems like an ideal candidate to do so.
VW may show the Phaeton U.S. consumers at the Detroit auto show in January 2014 in preparation for its eventual return. Phaenton's US comeback would complement the rollout of the carmaker's new SUVs as VW is planning to use the luxury sedan to show off its engineering prowess.
VW chief executive Martin Winterkorn confirmed to Bloomberg at a conference in Wolfsburg, Germany, this month the return of the Phaeton to the US. He remarked that a brand as large as VW needs a halo project in the upscale segment. "We've seen what happens to brands that don't have that kind of project," he told Bloomberg.
Read the entire article Volkswagen Phaeton to return to the United States
Vw planning to bring the new Phaeton and Microbus to the United States
Two of Volkswagen's former vehicles will make a comeback in the U.S., according to the automaker's future product portfolio. Automotive News said that the two vehicles that will be returning are the Phaeton ultra-luxury sedan and a new three-row Bulli that takes inspiration from the original Volkswagen Microbus.
The Volkswagen Phaeton was phased out in 2006 due to poor sales. One reason cited was its high price. Customers didn't want to pay for a VW car that cost the same as the Mercedes-Benz S-Class.
Phaeton sales in the U.S. reached a peak of 1939 units in 2004, before falling to 820 in 2005 and declining further to only 235 in 2006. The report also said that the new version of the Phaeton will be launched in Europe in 2015, and that the car would arrive in the U.S. but the date is still unclear.
Read the entire article Vw planning to bring the new Phaeton and Microbus to the United States
Next-generation Vw Phaeton coming in 2015
We can expect a new Volkswagen Phaeton Mk2 to be launched in 2015. Its architecture will come from Audi. The new VW Phaeton, dubbed VW631, is to be built on MLM Evo (modular longitudinal matrix) which allows for a plug-in hybrid option, a body structure that uses a major amount of aluminum, and a layout that's a lot more advanced and is less nose-heavy.
In the past, VW chairman Martin Winterkorn has black-flagged the Avantissimo (A8-based) and the Passat Variant Plus (A6-derived) but there's a lot of potential for a second more practical bodystyle aside from the four-door notch that's nearly compulsory in this segment.
A five-door coupé version would be highly practical but the Volkswagen brand is likely to be better off with a more pragmatic shape that might be more spacious than a Superb Combi, as sleek as an Avant, and as lavish as the present Phaeton, says Car. What's certain is that the Phaeton MkII model would be slotted between A6 and A8 and will have a price that's lower than that of the current Phaeton.
Read the entire article Next-generation Vw Phaeton coming in 2015
Hyundai Equus might have Phaeton's fate in the US, or might be the new Lexus
All eyes are on how Hyundai's Equus sedan fares in the luxury car segment and how it compares to the launching of the Toyota's Lexus LS 400 in 1989 and Volkswagen's Phaeton experiment in 2003. The Equus sedan, which is priced below $60,000 in the US, is being matched up against the models produced by these volume brands that were considered risky at the time.
On many accounts, the Equus sedan appears to be better groomed than these two models. Hyundai's volume goals for the Equus are modest. The company plans on boosting promotion at its mass-market dealerships for the big luxury sedan.
Notably, there isn't as much of a gap between the Equus and Hyundai's Genesis (which has soaring sales) than the Phaeton and the VW Passat or between the LS 400 and Toyota's range-topping Cressida sedan back in 1989.
Read the entire article Hyundai Equus might have Phaeton's fate in the US, or might be the new Lexus
2011 Vw Phaeton Facelift revealed ahead of the Beijing Auto Show
This is the 2011 Vw Phaeton Facelift, the latest generation of the German flagship sedan. Set to make its official debut tomorrow, at the Beijing Auto Show, the new car follows the same design line of the new Volkswagen models, showing a completely new front section but also modifications to its rear section and silhouette.
Also, the new car features several technical improvements such as Dynamic Light Assist (camera-based dynamic main beam regulation) and a navigation system that, if desired, can integrate online data from Google into the map display.
The new optional front camera enables drivers to see road signs, with speed limit signs visualized on the instrument panel and centre console's touchscreen. The new Phaeton will be available with a choice of two wheelbase options and two back seat versions (three seats / two individual seats).
Read the entire article 2011 Vw Phaeton Facelift revealed ahead of the Beijing Auto Show
2011 Vw Phaeton revealed at the Beijing Auto Show
The Volkswagen Phaeton, which has been slow in selling, has been upgraded. The revised luxury saloon was introduced today at the Beijing Auto Show. The launch venue was chosen precisely because it didn't sell so well in the UK and Europe but sells well in Asia. And in the US, it was pulled from sale completely in 2006.
The Phaeton's biggest markets are China and South Korea. VW sold 1400 Phaetons in China last year, a 40% compared to 2008 figures. However, these changes are mostly cosmetic.
VW's new Phaeton receives front-end styling shared by all new Volkswagens, including the Polo, Golf and Touareg. Styling tweaks have also been made at the rear.
Read the entire article 2011 Vw Phaeton revealed at the Beijing Auto Show
Vw to make a new Phaeton to take on 7-Series and S-Class
Instead of producing the Phaeton to compete with the 7-Series and S-Class in Europe, Volkswagen will modify the next generation of the car to the US and China markets. Since the Phaeton's launch in 2002, it has only sold a few units.
The Phaeton has just been facelifted and fitted with several internet connectivity features initially seen on the latest Audi A8, which it directly competes with. VW has plans to give the next Phaeton a new platform.
Insiders divulged that its styling and mechanical components will be steered towards the US (where sales of the Phaeton concluded in 2009) and China (where VW predicts to sell 3,000 of the current model this year).
Read the entire article Vw to make a new Phaeton to take on 7-Series and S-Class


by the depth of meaning in the simplicity of the story.
help other people in need.
life as a ransom for many".
prayer. Let us lift up the needs of those in distress to the Father of mercies.
Friday 13th February, 10:15am Mass (for Years 10-12).
will recommence on Friday 20th February.
God Bless you all. Let us continue to pray for one another.
I am filled with sorrow all day long.
no better than hired drudgery?
Restlessly I fret till twilight falls.
rights which the gospel gives me.
gospel, to have a share in its blessing.
R. Praise the Lord who heals the broken-hearted.
back Israel's exiles, he heals the brokenhearted, he binds up all their wounds.
each one by its name.
his wisdom can never be measured.
he humbles the wicked to the dust.
There is a new Saint John XXIII display.
College website) to the College office as soon as possible.
Why do we strike the breast three times?
practice as well as the priest.
The early Christians were familiar with the practice, as St. Augustine and St.
began to wait on them.
those who were possessed by devils.
off to a lonely place and prayed there.
'and became man', all bow.
of the Virgin Mary, and became man.
day in accordance with the Scriptures.
has spoken through the prophets.
costs, including wages of staff.
Elisa Ramos, Stevanus Hendradi T.R, .
Faith Formation – to support Fr.
come and be part of this meeting.
Fundraising - we are doing two raffles this year and we need more helpers!
And Also: Arturro Cobarrubias, Sandra Athay Mendoza.


text:
GAO: Geospatial sharing insufficient
By Joab Jackson
Although agencies are developing and deploying geospatial information systems to help battle wildlife fires, more interagency communications are needed to get their full value, according to a General Accounting Office report released this week.
The study, Geospatial Information: Technologies Hold Promise for Wildland Fire Management, But Challenges Remain, was requested by Reps. Mark Udall, D-Colo., and Joel Hefley, R-Colo., to find better ways to use geospatial systems in combating forest fires.
Greater senior-level support as well as the detailed plans on how to bring about interagency collaboration are needed to fully use these systems across agencies, the report concluded. It also said that once in place, such systems could be used by the Homeland Security Department and other agencies.
According to the report, about 7 million acres were burned in forest fires in 2002, costing the federal government $1.6 billion to suppress.
Geospatial information technologies, such as sensors and systems that analyze geographical information, can offer valuable information to firefighters in battle. For instance, first responders use a combination of satellite and aerial imagery, maps of vegetation, Global Positioning System data and specialized fire behavior modeling software to anticipate where a fire may spread.
An interagency working group called the National Wildfire Coordinating Group has several initiatives under way to facilitate more interagency communications. Also, the Office of Management and Budget's Geospatial One-Stop initiative was designed to make geospatial data standards easily available online.
However, there are roadblocks to more uses of existing systems, including difficulties in transferring data between systems, inadequate staffing and the difficulty in providing online access to first responders on the scene.
"Until effective interagency management of information resources and technology is a priority, the wildland fire community will likely continue to face challenges in effectively using geospatial information technologies," the reports said.
For the report, GAO focused on the work of five offices: the U.S. Forest Service, the Bureau of Indian Affairs, the Bureau of Land Management, the Fish and Wildlife Service and the National Park Service.
Joab Jackson is the senior technology editor for Government Computer News.


text:
Q: What is the Language neutral, User default LANGID, and System default LANGID? From MSDN about the FormatMessage function:

If you pass in zero, FormatMessage looks for a message for LANGIDs in
  the following order:

*

*Language neutral

*Thread LANGID, based on the thread's locale value

*User default LANGID, based on the user's default locale value

*System default LANGID, based on the system default locale value

*US English

But zero is Language neutral already, because the value of Language neutral is 0...
LCID lang = MAKELANGID(LANG_NEUTRAL, SUBLANG_NEUTRAL); // 0

What is the Language neutral? Is it the same for any computer? If "yes" then is it en-US?
Also what is the System default LANGID? Is it the same like on the screen?

Also what is the User default LANGID? What distinction between these three localizations? Where their values are stored in the Windows OS settings?

A: The MSDN documentation for FormatMessage could be easier to understand if it said language-neutral instead of Language neutral. Windows MUI resources can be language-specific or language-neutral (you can learn more about this topic here). Calling FormatMessage with dwLanguageId=0 tells Windows to try to load a string with the given dwMessageID from the language-neutral resources. If the string does not exist in the language-neutral resources Windows will try to load it from language-specific resources, using the documented order of LANGIDs (thread default, user default, system default, 1033). This is a bit unusual because the process default LANGID is not considered.
The User default LANGID is what you get back from calling  GetUserDefaultUILanguage. You can change it in the Control Panel (for Windows 8.1: Control Panel\Clock, Language, and Region\Language). GetSystemDefaultUILanguage returns the System default LANGID. I would expect that you can change it on the screen that you posted, but I am not sure if the upper or the lower button is the right one. I am afraid I don't know where these settings are stored.

A: According to leaked Windows XP source code (NT/base/ntos/rtl/ldrrsrc.c):
// If search path includes a language id, then attempt to
// match the following language ids in this order:
//
//   (0)  use given language id
//   (1)  use primary language of given language id
//   (2)  use id 0  (neutral resource)
//   (3)  use thread language id for console app
//
// If the PRIMARY language id is ZERO, then ALSO attempt to
// match the following language ids in this order:
//
//   (4)  use user UI language
//   (5)  use lang id of TEB for windows app if it is different from user locale
//   (6)  use UI lang from exe resource
//   (7)  use primary UI lang from exe resource
//   (8)  use Install Language
//   (9)  use lang id from user's locale id
//   (10)  use primary language of user's locale id
//   (11) use lang id from system default locale id
//   (12) use lang id of system default locale id
//   (13) use primary language of system default locale id
//   (14) use US English lang id
//   (15) use any lang id that matches requested info


Image Title: Elegant Bifold Bathroom Door Home Pinterest Throughout Prepare 11. Post Title: Bifold Bathroom Door. Filename: elegant-bifold-bathroom-door-home-pinterest-throughout-prepare-11.jpg. Image Dimension: 550 x 343 pixels. Images Format: jpg/jpeg. Publisher/Author: Gayle Fay. Uploaded Date: Tuesday - October 23rd. 2018 19:23:31 PM. Category: Architecture. Image Source: houzz.com. Doors Inside 0. Bifold 7. Com Door Ideas Home For Bathroom Decor Designs Rachel Merlinfroyd Intended Throughout To Bishop 1. With And Pertaining GrillesNGlass 9. Bi Singapore Regarding Plan HomeReliance Result 12. 13. Regard Reliance 8. In Gallery The 3. Fold Using Image I Transitional 17. Prepare Toilet 5.


Whilst we encourage everyone to have a fun time and be themselves, we encourage the following guidelines to keep everyone safe whilst having the best experience possible.
This is a leave no trace festival – littering will not be permitted and we are enforcing this policy to build awareness, appreciation and respect for our natural and cultural heritage. We share this land with natural wildlife, please respect their home! For the duration of the event please use bins provided and ensure your campsite is kept clean.
Esoteric is a no BYO alcohol event. If you are looking for alcohol there will be a licensed bar on site with affordable prices and a large range of your favourites. As part of our license, we must enforce car searches for alcohol at the gate.
The following gate opening times apply, please do not arrive to the gate outside of these times as you will be asked to wait till the opening hours.
If your birthday is between 6-9 March then it's our shout but you must have a birthday eticket! Birthday ticket requests will be available soon!
For local-friendly discounts that applies only to those who hold residency within Buloke Shire. Buloke local ticket requests will be available soon!
No passouts – shuttle buses are provided to access the nearby town Donald.
Keep hydrated – dehydration is the main cause of hospital visits, there are water stations located throughout the festival site, some of which run directly to the stages. Now you won't miss one banging tune to fill your water bottle.
Total fire ban- this includes gas ovens, candles, sparklers, generators and unauthorised fire twirling (any fire twirling must be pre-approved in writing by the organisers).
Look out for fellow Escoterican's – if you see someone in trouble, help them!
Outdoor activities such as these are quite physical, you must keep yourself safe and enter at your own risk.
St John Ambulance will be onsite for your safety, they are Australia's leading supplier of first aid services and training.
The trusted security services of NSA Security will be used throughout the event. If you see something not quite right then you are encouraged to let our friendly security crew know.
Firetac emergency response teams are trained and qualified to deal with any situation or incident that presents, especially when it comes to a fire. If Firetac requests anything relating to fire safety from you then please respect their decisions to make the best call on your behalf.
All stages are nestled in between a beautiful gum tree plantation that provides great shade for the majority of the day. However, it is still important to wear sunscreen to protect yourself from the harsh UV rays.
Sunglasses warm clothes – it gets cold at night!
No byo alcohol – There is a bar on site overlooking the main stage, this area is strictly an 18+ zone and will be serving a range of alcoholic drinks and bags of ice at affordable prices.


text:
Мінц Климентій Борисович (1908—1995) — російський кінодраматург.

З життєпису
Народ. 21 січня 1908 р. в Катеринбурзі. Закінчив інститут масових видовищ і урочистостей в Ленінграді (1925). Навчався на кінофакультеті Ленінградського інституту історії мистецтв (1925—1930).

Був одним з організаторів «Фабрики радянського сценарію» в Ленінграді (1928).

Автор сценарію фільму «Приборкувачка тигрів» (1954)

Автор сценарію української стрічки «Одного чудового дня» (1955, у співавт.).

Література

 Сценаристи советского художественного кино. М., 1972. — С.234.

Російські кінодраматурги


Long Throw Evaporation optimizes the thermal evaporation of indium and other materials for solder bump structures using "lift-off" vacuum deposition. Long throw layout and evaporation sources have capability which provides high volume anisotropic evaporant flux with the uniformity and directionality to cover and fill high aspect ratio features patterned on substrates. High quality vacuum and substrate temperature control add to film quality for high-yield applications.
The Nanochrome I Long Throw Evaporator targets the requirements in "lift-off" deposition.


We meet with celebrity photographer George Holz at The Polo Lounge at The Beverly Hills Hotel to talk about his 40-year career and how everything started with assisting Helmut Newton.
We visit actress Charlotte Taschen on a rainy day in her future L.A. home. She talks about what it was like growing up as the daughter of one of the most iconic art collectors and art book publishers and her move from Germany to Hollywood.
David Chokachi, whose acting career began on "Baywatch" in the '90s, today splits his time between his Hollywood home and Malibu beach house. We visit him twice and join him for an intimate beach day with his daughter at his favorite surf spot.
Two of Hollywood's brightest visual effects supervisors discuss their work with Kenzo, Spike Jonze, digital humans, water, smoke, fog, snow, and fire.
Renowned interior and portrait photographer Roland Beaufre talks about his travels, his work with famous subjects, and his never-ending fascination with unconventional places.
We talk to Gil Rigoulet who became the first official photographer of Le Monde in the early '80s. Today he mainly works on personal projects.
Architect-turned-photographer Fred Guillaud takes us on a quiet, photojournalistic journey and lets us see the world through his lens.
Alongside his photography and personal diary fragments, artist Nick Turner talked to us about horses and some of his most emotional moments in life.
Renowned photographer and traveler Kevin Russ takes The Unseasonal on a world tour. Fasten your seatbelts and let us take your breath away.
A year-long dialogue with American artist-turned-architect and punk modernist Robert Stone about his unique approaches and perfect backdrops for the fashion world's upper crust.
A conversation with black-and-white photographer John Ciamillo about his working methods and mixing portrait and street photography.
We sat down with acclaimed fashion, portrait, and beauty photographer Paul Westlake to discuss inspiration, the 'ah-ha' moment, and his ongoing love of analog.


Please complete the form below and someone from the Gatas Team will get back to you as soon as possible.
How soon do you need to have your home sold and why is that important to you?
What improvements have you made on your home?
How much do you need to net after expenses that would make you comfortable?
If so, How much do you want to spend and where do you want to live?
What is important to you and your family outside of work?
Professionally, how do you earn your living?
Indicate date you are available for a meeting.


Welcome to the micro world! Create micro drawings on the go! Bring your drawings to life with four fantastic frames of action! Save your favorite creations to your Personal Computer!
- Start drawing on white pixels to draw with black pixels.
- Start drawing on black pixels to draw with white pixels.
Pencil - Touch in the Drawing Area to draw. You can also drag.
Paint Blop - Touch in the Drawing Area to fill an enclosed region.
Line - Drag to draw a straight line.
Square / Rectangle - Drag from corner to corner to draw a rectangle.
Circle / Ellipse - Drag from center point to circumference to draw an ellipse.
Nudge - Touch any nudge arrow to move the entire drawing one pixel in the direction indicated by the arrow. The drawing will wrap around the edges.
Clear - Erase the entire frame.
Invert - Invert the colors of the drawing.
Life - The miracle of life.
Copy - Touch this tool once to enter copy mode. Then touch a frame selector to copy the current frame to that frame. Or touch the copy tool again to cancel.
Undo - Touch to fix your mistake.
Redo - Touch to fix your mistaken undo.
Touch these to select different frames of your animation.
This is where you create your masterpiece.
Watch your animation in a continuous loop.
Press this button to export your masterpiece to your Personal Computer using the Super Export Cable.


Best slow roasted BBQ ribs you ever had.
If you want to try them you have 2 choices. Number one, you can make them at home and number two, you can visit SISSI Restaurant & Wine in Kraków, Poland where they are served.
THE RIBS: cut out and discard any excess fat pieces and membranes from the bones. Chop the ribs into smaller chunks (3ribs in each will be perfect). Place the leftover ingredients (from the ribs ingredients section) in a food processor and blend with a blender until you get a marinade. Smear the marinade over the ribs and place them in a deeper baking tray. Cover with aluminum foil (the matt side up) and place into the oven. Bake for 3 hours at 160°C.
THE SAUCE: Heat up a bigger pot and add the vegetable oil, onions, chili flakes, garlic and the cumin. Roast for several minutes and then add the balsamic vinegar. Leave it to evaporate a bit and then add the soy sauce and the Worchester sauce. Bring to boil and add the ketchup, smoke flavor, cane sugar and the sugar molasses. Bring to boil and switch off the heat. Leave to cool and then blend with a blender until you get a smooth sauce.
BAKED MASHED POTATOES: place the mashed potatoes into ramekins and add the grated cheese on top. Bake in the oven at 160°C for 10 minutes.
Serving proposal: place the ribs on a bigger plate and pour over with the sauce. Serve with baked mashed potatoes and pickles on the side.
A day in a restaurant kitchen.